Abstract: An electrolytically reduced water which consists of an alkali ion water prepared by ion exchange and has a dissolved hydrogen concentration of 0.20 ppm or above, an oxidation-reduction potential of ?150 mV to ?500 mV, and a hydrogen ion component of pH6.5-10.5 and which is quantitatively specified in the reducing power capable of inhibiting the oxidative deterioration of fat in the cutis through the elimination of active oxygen due to the characteristics of hydrogen, the oxidation-reduction potential characteristics of high reducing action, and alkaline characteristics and can activate the skin to inhibit the oxidative deterioration and suppress lumpy fat (cellulite).

Abstract: A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition is reduced in side effects, has the high ability to eliminate free radicals in the body, and further has excellent preparation stability.

Abstract: A pharmaceutical preparation comprising at least one L-ascorbic acid derivative and at least one antimalignant tumor agent, wherein said L-ascorbic acid derivative provides, on culturing zooblast for 20 hours in a culture medium containing the L-ascorbic acid derivative in a concentration of 5 &mgr;M, an L-ascorbic acid intracellular cumulative amount equal to or greater than that obtained by culturing the zooblast in a culture medium containing magnesium L-ascorbic acid-2-phosphate in a concentration of 50 &mgr;M. Also disclosed is a method of inhibiting cancer metastasis which comprises administering to a person in need of such treatment a dosage effective amount of the L-ascorbic acid derivative. Also disclosed is a method of treating cancer which comprises administering to a person in need of such treatment a dosage effective amount of the pharmaceutical preparation.

Abstract: An L-ascorbic acid drug for intracerebral administration comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents. Also disclosed is a method for increasing intracerebral concentration of L-ascorbic acid in a human being comprising administering by injection an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds. Additionally disclosed is a method for increasing intracerebral concentration of L-ascorbic acid in a human being comprising administering by injection an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents.

Abstract: Presented are pharmaceutical carcinostatic compositions comprising as active ingredient a diol represented by the formula: ##STR1## wherein n is an integer of 6 to 33; or by the formula: ##STR2## wherein R is hydrogen or C.sub.1 to C.sub.5 alkyl and m is an integer of 3 to 21; and methods of treatment of cancer of animals with a diol represented by the above formulas. The compositions and the methods are useful for cancer treatment without causing side effects.

Abstract: A pharmaceutical composition comprising, in admixture with a pharmacologically acceptable carrier, an isomonool of the formula ##STR1## wherein R is an alkyl group with 1 to 5 carbon atoms, and n is an integer of 4 to 22, have carcinostatic, carcinostasis-reinforcing and carcinogenesis-preventing activity.